This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Parsons Stock Gains 49% in a Year: What Should Investors Do Now?
by Arghyadeep Bose
Given the recent rise in PSN shares, we analyze its current position to determine whether you should buy, hold or sell it.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Cardlytics (CDLX)
by Zacks Equity Research
Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 54.55% and 19.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Jacobs Solutions (J) Q3 Earnings Beat Estimates
by Zacks Equity Research
Jacobs Solutions (J) delivered earnings and revenue surprises of 0.51% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardlytics (CDLX) delivered earnings and revenue surprises of 44.19% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Spotify (SPOT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Spotify (SPOT) delivered earnings and revenue surprises of -111.25% and 2.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardlytics (CDLX) Surges 13.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CleanSpark (CLSK) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CleanSpark (CLSK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Cardlytics (CDLX) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how Cardlytics (CDLX) and Trane Technologies (TT) have performed compared to their sector so far this year.
Does Cardlytics (CDLX) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 49.3% upside potential for Cardlytics (CDLX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.